Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
681 to 700 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. | J Exp Clin Cancer Res | 2023 | 36755269 | PubTator, text mining | PubMed |
| Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. | J Immunother Precis Oncol | 2023 | 36751656 | PubTator, text mining | PubMed |
| Whole exome sequencing and replication for breast cancer among Hispanic/Latino women identifies FANCM as a susceptibility gene for estrogen-receptor-negative breast cancer. | medRxiv | 2023 | 36747679 | PubTator, text mining | PubMed |
| Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study. | Cancer Sci | 2023 | 36747324 | PubTator, text mining | PubMed |
| Pulmonary Artery Intimal Sarcoma in a Patient with Lynch Syndrome: Response to an Immune Checkpoint Inhibitor. | Case Rep Oncol | 2023 | 36743879 | PubTator, text mining | PubMed |
| Proactive breast cancer risk assessment in primary care: a review based on the principles of screening. | Br J Cancer | 2023 | 36737659 | PubTator, text mining | PubMed |
| Integrated Whole-Exome and Transcriptome Sequencing Indicated Dysregulation of Cholesterol Metabolism in Eyelid Sebaceous Gland Carcinoma. | Transl Vis Sci Technol | 2023 | 36735267 | PubTator, text mining | PubMed |
| A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer. | Comput Struct Biotechnol J | 2023 | 36733702 | PubTator, text mining | PubMed |
| Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers. | Gynecol Oncol | 2023 | 36724586 | PubTator, text mining | PubMed |
| Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. | JCO Precis Oncol | 2023 | 36716415 | PubTator, text mining | PubMed |
| Differential requirement for BRCA1-BARD1 E3 ubiquitin ligase activity in DNA damage repair and meiosis in the Caenorhabditis elegans germ line. | PLoS Genet | 2023 | 36716349 | PubTator, text mining | PubMed |
| Germline heterozygous exons 8-11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding? | Hered Cancer Clin Pract | 2023 | 36709314 | PubTator, text mining | PubMed |
| MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer. | BMC Cancer | 2023 | 36707770 | PubTator, text mining | PubMed |
| FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. | Eur J Hum Genet | 2023 | 36707629 | PubTator, text mining | PubMed |
| DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation. | Nat Commun | 2023 | 36702902 | PubTator, text mining | PubMed |
| Genetic determinants and absence of breast cancer in Xavante Indians in Sangradouro Reserve, Brazil. | Sci Rep | 2023 | 36702877 | PubTator, text mining | PubMed |
| Protein degradation: expanding the toolbox to restrain cancer drug resistance. | J Hematol Oncol | 2023 | 36694209 | PubTator, text mining | PubMed |
| ASGR1: an emerging therapeutic target in hypercholesterolemia. | Signal Transduct Target Ther | 2023 | 36690631 | PubTator, text mining | PubMed |
| The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer. | Int J Mol Sci | 2023 | 36675020 | PubTator, text mining | PubMed |
| High Glucose Increases DNA Damage and Elevates the Expression of Multiple DDR Genes. | Genes (Basel) | 2023 | 36672885 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=35